ESR1 and triple-negative breast carcinoma: BC molecular subtype analysis based on ER, PR, HER2, and Ki67 markers revealed that 16.98% were Luminal type A (LA), 35.85% were Luminal type B (LB), 13.2% were LB-HER2+ type, 5.66% were HER2+ type, and 28.3% were triple negative breast cancer (TNBC) type.